NO173446B - Analogifremgangsmaate til fremstilling av nye, terapeutiskaktive, substituerte alkandifosfonsyrer - Google Patents
Analogifremgangsmaate til fremstilling av nye, terapeutiskaktive, substituerte alkandifosfonsyrer Download PDFInfo
- Publication number
- NO173446B NO173446B NO87874856A NO874856A NO173446B NO 173446 B NO173446 B NO 173446B NO 87874856 A NO87874856 A NO 87874856A NO 874856 A NO874856 A NO 874856A NO 173446 B NO173446 B NO 173446B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- acid
- compound
- hydroxy
- free
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 16
- 150000007513 acids Chemical class 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- -1 5-membered heteroaryl radical Chemical group 0.000 claims abstract description 25
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 10
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims abstract description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 20
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 11
- 239000007858 starting material Substances 0.000 claims description 7
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 claims description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 abstract description 8
- 150000002367 halogens Chemical class 0.000 abstract description 8
- 125000003545 alkoxy group Chemical group 0.000 abstract description 6
- 230000003913 calcium metabolism Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 12
- 230000008018 melting Effects 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229910052783 alkali metal Inorganic materials 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 150000003973 alkyl amines Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- STJWVOQLJPNAQL-UHFFFAOYSA-N 1-[diethoxyphosphorylmethyl(ethoxy)phosphoryl]oxyethane Chemical compound CCOP(=O)(OCC)CP(=O)(OCC)OCC STJWVOQLJPNAQL-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- QLRDCTNWBMCWRF-UHFFFAOYSA-N 1-benzyl-2-[2,2-bis(diethoxyphosphoryl)ethyl]imidazole Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)CC1=NC=CN1CC1=CC=CC=C1 QLRDCTNWBMCWRF-UHFFFAOYSA-N 0.000 description 2
- RJEIYQLLAGSIFO-UHFFFAOYSA-N 2-(1-methylimidazol-2-yl)acetic acid;hydrochloride Chemical compound Cl.CN1C=CN=C1CC(O)=O RJEIYQLLAGSIFO-UHFFFAOYSA-N 0.000 description 2
- MHLHKDRIKYOMBQ-UHFFFAOYSA-N 2-[2,2-bis(diethoxyphosphoryl)ethyl]-1h-imidazole Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)CC1=NC=CN1 MHLHKDRIKYOMBQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- VVTWQGRTVMQHIS-UHFFFAOYSA-N [2-(1-benzylimidazol-2-yl)-1-hydroxy-1-phosphonoethyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=NC=CN1CC1=CC=CC=C1 VVTWQGRTVMQHIS-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- NGMZSXZBZNXBGX-UHFFFAOYSA-N (1-phosphono-2-pyridin-2-ylethyl)phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)CC1=CC=CC=N1 NGMZSXZBZNXBGX-UHFFFAOYSA-N 0.000 description 1
- SDOFMBGMRVAJNF-SLPGGIOYSA-N (2r,3r,4r,5s)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-SLPGGIOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- ONRFTBGCNJFRKU-UHFFFAOYSA-N 1-[2,2-bis(diethoxyphosphoryl)ethyl]imidazole Chemical compound CCOP(=O)(OCC)C(P(=O)(OCC)OCC)CN1C=CN=C1 ONRFTBGCNJFRKU-UHFFFAOYSA-N 0.000 description 1
- IOOCHXMDSFPOGL-UHFFFAOYSA-N 1-benzyl-2-chloromethylimidazole hydrochloride Chemical compound [H+].[Cl-].ClCC1=NC=CN1CC1=CC=CC=C1 IOOCHXMDSFPOGL-UHFFFAOYSA-N 0.000 description 1
- BMZHQSYXCWLVBE-UHFFFAOYSA-N 2-(1-benzylimidazol-2-yl)acetonitrile Chemical compound N#CCC1=NC=CN1CC1=CC=CC=C1 BMZHQSYXCWLVBE-UHFFFAOYSA-N 0.000 description 1
- ULLPVWHGYZANAK-UHFFFAOYSA-N 2-(1-methylimidazol-2-yl)acetonitrile;hydrochloride Chemical compound Cl.CN1C=CN=C1CC#N ULLPVWHGYZANAK-UHFFFAOYSA-N 0.000 description 1
- JDIPKQBKSBWIKU-UHFFFAOYSA-N 2-(chloromethyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=CN=C1CCl JDIPKQBKSBWIKU-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKZJSYXGKHQHRA-UHFFFAOYSA-N 2-imidazol-1-ylacetic acid;hydrochloride Chemical compound Cl.OC(=O)CN1C=CN=C1 JKZJSYXGKHQHRA-UHFFFAOYSA-N 0.000 description 1
- ISPIHWORPMENMZ-UHFFFAOYSA-N 3-(1h-imidazol-2-yl)propan-1-ol Chemical compound OCCCC1=NC=CN1 ISPIHWORPMENMZ-UHFFFAOYSA-N 0.000 description 1
- DKFVEDKCRIZEEM-UHFFFAOYSA-N 3-(1h-imidazol-5-yl)propan-1-ol Chemical compound OCCCC1=CNC=N1 DKFVEDKCRIZEEM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RYZVYLGJZFNBND-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-ol Chemical compound OCCCN1C=CN=C1 RYZVYLGJZFNBND-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010049933 Hypophosphatasia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031240 Osteodystrophy Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WHSQHILWDWGNRB-UHFFFAOYSA-N [1-amino-2-(1-benzylimidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(N)CC1=NC=CN1CC1=CC=CC=C1 WHSQHILWDWGNRB-UHFFFAOYSA-N 0.000 description 1
- DTVMABUXNTUODY-UHFFFAOYSA-N [1-hydroxy-2-(1-methylimidazol-2-yl)-1-phosphonoethyl]phosphonic acid;hydrate Chemical compound O.CN1C=CN=C1CC(O)(P(O)(O)=O)P(O)(O)=O DTVMABUXNTUODY-UHFFFAOYSA-N 0.000 description 1
- WRMDPPUVIXTZPX-UHFFFAOYSA-N [1-hydroxy-2-(1h-imidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=NC=CN1 WRMDPPUVIXTZPX-UHFFFAOYSA-N 0.000 description 1
- YLVSLLZBOOEDFX-UHFFFAOYSA-N [1-hydroxy-2-(1h-imidazol-2-yl)-2-phosphonoethyl]phosphonic acid Chemical compound OP(=O)(O)C(O)C(P(O)(O)=O)C1=NC=CN1 YLVSLLZBOOEDFX-UHFFFAOYSA-N 0.000 description 1
- QJYHEVLLGQDDSN-UHFFFAOYSA-N [1-hydroxy-2-(1h-imidazol-5-yl)-1-phosphonoethyl]phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CNC=N1 QJYHEVLLGQDDSN-UHFFFAOYSA-N 0.000 description 1
- AQHSXXBYJSGKFY-UHFFFAOYSA-N [1-hydroxy-2-(2-methylimidazol-1-yl)-1-phosphonoethyl]phosphonic acid Chemical compound CC1=NC=CN1CC(O)(P(O)(O)=O)P(O)(O)=O AQHSXXBYJSGKFY-UHFFFAOYSA-N 0.000 description 1
- BDTDCXHWLYHYOO-UHFFFAOYSA-N [2-(1-methylimidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound CN1C=CN=C1CC(P(O)(O)=O)P(O)(O)=O BDTDCXHWLYHYOO-UHFFFAOYSA-N 0.000 description 1
- XFDRFWQRYYEEEI-UHFFFAOYSA-N [2-(1h-imidazol-2-yl)-1-phosphonoethyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)CC1=NC=CN1 XFDRFWQRYYEEEI-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 150000005690 diesters Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- MWHLCFYPFGFBQO-UHFFFAOYSA-N hydron;2-(1h-imidazol-5-yl)acetic acid;chloride Chemical compound Cl.OC(=O)CC1=CN=CN1 MWHLCFYPFGFBQO-UHFFFAOYSA-N 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- HSWGFBJLBMOGFL-UHFFFAOYSA-N imidazol-1-ylmethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCN1C=NC=C1 HSWGFBJLBMOGFL-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
- C07F9/6518—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Control Of El Displays (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Glass Compositions (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Foreliggende oppfinnelse vedrører fremstilling av nye, terapeutisk aktive, heteroarylalkandifosfonsyrer.
Nærmere bestemt vedrører oppfinnelsen en analogifremgangsmåte for fremstilling av nye, terapeutisk anvendbare hetero-arylalkandif osfonsyrer med formelen
hvor Ri betyr en usubstituert eller med C^-C^alkyl substituert imidazolylrest og R2 betyr hydroksy eller hydrogen og deres salter.
I det etterfølgende skal det som lavere rester og forbindelser eksempelvis forstås slike, som oppviser til og med 7, spesielt til og med 4, C-atomer. Videre har de generelle uttrykk eksempelvis følgende betydninger: Lavere alkyl er eksempelvis C^-C^alkyl, som metyl, etyl, propyl eller butyl, videre iso-, sekundær- eller tertiærbu-tyl, men kan også være en Cs-Cy-alkyl-, som pentyl, heksyl-eller heptylgruppe.
Salter av forbindelser med formel I er spesielt deres salter med farmasøytisk anvendbare baser, som ikke-toksiske metall-salter som er avledet fra metaller fra grupper Ia, Ib, Ila og Ilb, f.eks. alkalimetall-, spesielt natrium- eller kaliumsalter, jordalkalimetall-, spesielt kalsium- -eller magnesiumsalter, kobber-, aluminium- eller sinksalter, likeså ammoniumsalter med ammoniakk eller organiske aminer eller kvaternære ammoniumbaser, som eventuelt C-hydroksylerte, alifatiske aminer, spesielt mono-, di- eller trilaverealkyl-aminer, f.eks. metyl-, etyl-, dimetyl- eller dietylamin, mono-, di- eller tri-(hydroksylaverealkyl)-aminer, som etanol-, dietanol- eller trietanolamin, tris(hydroksymetyl)-amino-metan eller 2-hydroksytertiærbutylamin, eller N-(hydroksylaverealkyl)-N,N-dilaverealkylaminer hhv. N-(poly-hydroksylaverealkyl)-N-laverealkylaminer, som 2-(dimetyl-amino )-etanol eller D-glukamin, eller kvaternaere, alifatiske ammoniumhydroksyder, f.eks. med tetrabutylammoniumhydroksyd.
I denne sammenheng skal det også nevnes, at forbindelsene med formel I foreligger i form av indre salter, forsåvidt som gruppen R^ er basisk nok. Disse forbindelsene kan overens-stemmende med dette også overføres til de tilsvarende syreaddisjonssaltene ved behandling med en sterk protonsyre, som med en halogenhydrogensyre, svovelsyre, sulfonsyre, f.eks. metan- eller p-toluensulfonsyre, eller sulfaminsyre, f.eks. N-cykloheksylsulfaminsyre.
Forbindelsene med formel I og deres salter oppviser verdifulle farmakologiske egenskaper. Spesielt har de en utpreget regulerende virkning på kalsium-stoffskifte hos varmblodige dyr. Særlig bevirker de en utpreget hemming av knokkelre-sorpsjon hos rotter, hvilket lar seg påvise så vel i forsøksanordningen ifølge Acta Endocrinol. 78, 613-24 (1975) ved hjelp av den PTH-induserte stigning av serumkalsium-speilet etter subkutan tilførsel i doser på 0,01 til 1,0 mg/kg, som også i TPTX (thyroparatyroidektomisert)-rottemodellen ved hjelp av den med vitamin D3 utløste, eksperimentelle hyperkalsemi etter subkutan tilførsel av doser på 0,0003 til 1,0 mg. Likeså hemmes den tumorhyper-kalsemi som er indusert ved Walker-256-tumorer, etter peroral tilførsel av 1,0 til 100 mg/kg.
I den nevnte modellen ble det for de nedenfor angitte forbindelsene funnet de i tabellen angitte verdiene for den ved vitamin D3 utløste knokkelresorpsjonen i TPTX-rotte.
2-(imidazol-2-yl )-l-hydroksy-etan-l,1-difosfonsyre (I), ifølge NO-patentsøknad nr. 874856,
2-(metylimidazol-2-yl)-l-hydroksy-etan-l,1-
difosfonsyre (II), ifølge NO-patentsøknad nr. 874856,
2-(raetylimidazol-2-yl)-etan-l,1-difosfonsyre (III), ifølge NO-patentsøknad nr. 874856,
2-(imidazol-l-yl)-l-hydroksy-etan-l,1-
difosfonsyre (IV), ifølge NO-patentsøknad nr. 874856,
2-[4(5)-metylimidazol-5(4)-yl]-1-hydroksy-etan-1,1-difosfonsyre (V), ifølge NO-patentsøknad nr. 874856,
2- (pyrid-2-yl)-etan-l,1-difosfonsyre (VI), ifølge EP-patentsøknad nr. 186405,
3- (imidazol-l-yl)-l-hydroksy-propan-
1,1-difosfonsyre (VII), ifølge DE-A-3428524, hhv. EP-A-170228,
3-(imidazol-2-yl)-l-hydroksy-propan-
1,1-difosfonsyre (VIII), ifølge DE-A-3428524, hhv. EP-A-170228,
3-(imidazol-4-yl)-l-hydroksy-propan-
1,1-difosfonsyre (IX), ifølge DE-A-3428524, hhv. EP-A-170228.
Videre viser de en tydelig hemming på den fremadskridende, kronisk-artritiske prosessen i Adjuvansartriten hos rotter i forsøksanordningen etter Newbould, Brit. J. Pharmacology 21, 127 (1963) såvel som etter Kaibara et al., J. Exp. Med. 159, 1388-96 (1984) i doser på 0,001 til 1,0 mg/kg subkutant. De er derfor utmerket egnet som aktive legemiddelstoffer for behandling av sykdommer, som kan bringes i forbindelse med kalsiumstoffskiftet, eksempelvis betennelsesprosesser i ledd, degenerative prosesser i leddbrusken, av Osteoporose, Periodontit, Hyperparatyreoidisme og av kalsiumavleiringer i blodkar eller på protetiske implantater. Gunstig påvirket blir såvel sykdommer, ved hvilke det kan fastslås en anomal avleiring av tungtløslige kalsiumsalter, som i slike av formkretsen av Artrit, f.eks. Morbus Bechterew,Neurit, Bursit, Periodontit og Tendinit, Fibrodysplasi, Osteoartrose eller Artereosklerose, som også slike, ved hvilke en anomal oppløsning av hårdt kroppsvev står i forgrunnen, som den arvelige Hypofosfatasi, degenerative prosesser i leddbrusken, Osteoporoser av forskjellig opprinnelse, morbus Paget og Osteodystrofi fibrosa, likeså osteolytiske prosesser som utløses ved tumorer.
Oppfinnelsen gjelder især fremstillingen av de forbindelser med formel I og deres salter som er nevnt i eksemplene, særlig deres indre salter og farmasøytisk anvendbare salter med baser.
Fremgangsmåten ifølge oppfinnelsen for fremstilling av forbindelsene med formel I og deres salter er kjennetegnet ved at man
a) i en ved et substituerbart N-atom i resten R^ eventuelt midlertidig beskyttet forbindelse med formelen
hvor Ri og R2 har de angitte betydningene, Xj betyr en funksjonelt omdannet og X2 en fri eller funksjonelt omdannet fosfonogruppe, overfører X^ og eventuelt X2 til den frie fosfonogruppen eller b) omsetter en på et substituerbart N-atom i resten R^ eventuelt midlertidig beskyttet forbindelse med formelen hvor X3 betyr en karboksy—, karbamyl—, iminoeter—, imino-ester— eller cyanogruppe og R^ har den angitte betydningen, med fosforsyrling og fosfortriklorid, og om ønsket overfører en oppnådd forbindelse til en annen forbindelse med formel I og/eller overfører en oppnådd fri forbindelse til et salt eller et oppnådd salt til den frie forbindelsen eller til et annet salt. Ifølge fremgangsmåtevariant a) foreligger eksempelvis funksjonelt omdannede fosfonogrupper som skal overføres til fosfono i en esterform, spesielt en diesterform med formelen -P(=0)(0R)2 (IV), hvor OR eksempelvis betyr laverealkoksy eller en fenyloksygruppe som eksempelvis er substituert med laverealkyl, laverealkoksy, halogen, trifluormetyl og/eller hydroksy.
Overføringen av en funksjonelt omdannet til den frie fosfonogruppen foregår på vanlig måte ved hydrolyse, eksempelvis i nærvær av en mineralsyre, som bromhydrogen-, klorhydrogen-eller svovelsyre, eller ved omsetning med et trilaverealkyl-halogensilan, f.eks. med trimetylklorsilan i nærvær av natriumjodid eller spesielt trimetyljodsilan eller trimetylbromsilan, fortrinnsvis under avkjøling, f.eks. i et tempera-turområde på 0 til 25°C.
Utgangsstof fene med formel II, hvor R2 er hydroksy, kan eksempelvis fremstilles ved at en forbindelse med formelen
eller fortrinnsvis nitrilet eller syrekloridet av den samme omsettes med en tilsvarende fosforsyrlingtriester med formelen P(0R)3 (Ilb), hvor R eksempelvis betyr laverealkyl, i nærvær av et trilaverealkylamin, f.eks. trietylamin, til et mellomprodukt, rimeligvis en forbindelse med formelen og denne videreomsettes med en fosforsyrlingdiester med formelen E-P(=0)(0R)2 (Ild) hhv. P(0H)(0R)2 (Ile), hvor R eksempelvis betyr laverealkyl, i nærvær av et alkalimetal-laverealkanolat, f.eks. av natriummetanolat, til den tilsvarende forbindelse med formelen Forbindelser Ila oppnås eksempelvis ved at en tilsvarende forbindelse med formelen med en sterk base, eksempelvis en av de metallbaser som er nevnt under fremgangsmåtevariant a), overføres til karbeniatsaltet og dette omsettes med karbondioksyd eller ved at en forbindelse med formelen hvor Y betyr reaksjonsdyktig, forestret hydroksy, spesielt halogen, som brom, overføres med et alkalimetallcyanid, f.eks. med natrium- eller kaliumcyanid i det tilsvarende nitril (Hg; Y = CN), og dette hydrolyseres til syren, spesielt under basiske betingelser. Utgangsstoffer II, hvor Rg er hydrogen, oppnås eksempelvis, ved at en forbindelse med formelen hvor Y betyr reaksjonsdyktig, forestret hydroksy, spesielt halogen, som brom, i nærvær av en metallbase, som hydridet, et amid eller en hydrokarbonforbindelse av et alkalimetall, f.eks. av natriumhydrid, natriumamid, ditrimetylsilylnatrium-amid eller butyllitium, omsettes med en metandifosfonsyre-ester, f.eks. med formelen
hvor R eksempelvis betyr laverealkyl.
Utgangsstoffer med formel II, hvor resten R^ er bundet via et N-atom og Rg står for hydrogen eller hydroksy, kan også fremstilles, ved at en tilsvarende forbindelse med formelen
i nærvær av en sterk metallbase som et alkalimetall- eller
jordalkalimetallhydrid, f.eks. av natriumhydrid, omsettes med en forbindelse med formelen
hvor X^ og Xg særlig betyr grupper med formelen IV.
I utgangsstoffer med formel III for fremgangsmåtevariant b) er iminoeter- hhv. iminoestergrupper eksempelvis slike med formelen -C(=NH)-X3' (III'), hvor X3' betyr foretret eller forestret hydroksy, som laverealkoksy, en fenoksygruppe, laverealkanoyloksy, en benzoyloksygruppe eller et halogen-atom, f.eks. klor. Forbindelser III, hvor X3 betyr en av de nevnte grupper III', kan også foreligge som salter, som mineralsyresalter, f.eks. som hydrohalogenider.
Omsetningen av forbindelser med formel III med fosforsyrling og fosfortriklorid foregår på vanlig måte, hvorved fosforsyr-lingbestanddelen fortrinnsvis dannes in situ ved reaksjon av overskudd fosfortriklorid med vannholdig fosforsyre, f.eks. med handelsvanlig, 75^-ig til 95%- ig, fortrinnsvis 85#-ig fosforsyre. Omsetningen gjennomføres fordelaktig under oppvarming, f.eks. til ca. 70 til ca. 120°C i et egnet løsningsmiddel, som tetrakloretan, trikloretan, klorbenzen, klortoluen eller paraffinolje, og under hydrolytisk opparbeidelse .
Utgangsstoffene med formel III kan, forsåvidt som de ikke er kjente, eksempelvis fremstilles, ved at en tilsvarende forbindelse med formelen
overføres til karbeniatsaltet med en sterk base, eksempelvis en av de metallbaser som er nevnt under fremgangsmåtevariant a), og dette omsettes med karbondioksyd eller en forbindelse med formelen Y-X3 (Illb), hvor Y betyr halogen, som klor
eller brom, f.eks. med et karbamylhalogenid, iminoeterhaloge-nid eller frem for alt et halogencyan, som klorcyan.
For den midlertidige beskyttelsen av et substituerbart N-atom i resten R-^ egner de vanlige N-beskyttelsesgruppene og innførings- og avspaltningsfremgangsmåtene for disse seg, eksempelvis dilaverealkoksymetylgrupper, som dimetoksymetyl, som kan avspaltes ved syrebehandling, 2,2,2-trihalogen-, som 2,2,2-trijod-, 2,2,2-tribrom- eller 2,2,2-trikloretoksykarbo-nylrester, som kan avspaltes f.eks. ved behandling med sink i eddiksyre, a-fenyllaverealkoksykarbonylrester, som karbobenz-oksy eller trityl, som f.eks. kan avspaltes ved katalytisk hydrering, såvel som laverealkansulfonylgrupper som metansul-fonyl, som f.eks. kan avspaltes ved behandling med bis(2-metoksyetoksy)-natriumaluminiumhydrid, men også på samme måte a-fenylalkyl- eller alkylgrupper, hvis avspaltning behandles i det etterfølgende.
Forbindelser med formel I, hvor R2 er amino, kan overføres til de tilsvarende forbindelsene I, hvor R2 er hydroksy, ved behandling med saltpetersyri ing. Behandlingen med salt-petersyrling foregår på vanlig måte under frigivelse av denne i vandig løsning fra et av dens salter, f.eks. fra natriumnitritt, ved syrebehandling, f.eks. innvirkning av saltsyre, hvorved det midlertidig dannes et tilsvarende, ustabilt diazoniumsalt, f. eks. -klorid, som under innføring av cx-hydroksygruppe avspalter nitrogen.
Oppnådde, frie forbindelser med formel I innbefattende deres indre salter med formel I kan overføres til basesaltet ved partiell eller fullstendig nøytralisasjon med en av de innledningsvis nevnte basene. På analog måte kan også syreaddisjonssalter overføres til de tilsvarende frie forbindelsene, hhv. deres indre salter.
Omvendt kan oppnådde, frie forbindelser med formel I overfø-res til syreaddisjonssalter med formel I" ved behandling med en av de innledningsvis nevnte protonsyrene.
Oppnådde salter kan på i og for seg kjent måte omdannes til de frie forbindelsene, f.eks. ved behandling med et surt reagens, som en mineralsyre, f.eks. en base, f.eks. alkali-lut.
Forbindelsene innbefattende deres salter kan også oppnås i form av deres hydrater eller innbefattende det løsningsmiddel som anvendes for krystallisasjonen.
Som følge av det nære slektskapet mellom de nye forbindelsene i fri form og i form av deres salter skal det i det foranstå-ende og etterfølgende under frie forbindelser eller deres salter eventuelt også forstås de tilsvarende saltene hhv. frie forbindelsene.
Ved fremgangsmåten ifølge foreliggende oppfinnelse anvendes fortrinnsvis slike utgangsstoffer, som fører til forbindelser som innledningsvis er nevnt som særlig verdifulle.
De etterfølgende eksemplene illustrerer den ovenfor beskrevne oppfinnelse. Temperaturer er angitt i °C.
Eksempel 1:
8,6 g (0,053 mol) imidazol-4-yleddiksyre-hydroklorid oppvarmes med 7,1 ml 85#-ig fosforsyre og 25 ml klorbenzen under omrøring og tilbakeløp til 100°. Så tildryppes ved 100° 13,9 ml fosfortriklorid, hvorved det finner sted gassutvikling. Reaksjonsblandingen utskiller i løpet av 30 minutter en tykk masse. Det oppvarmes ennå i 3 timer til 100° og det overstående klorbenzen dekanteres så av. Den tilbakeblivende, seige massen oppvarmes med 40 ml 9-n saltsyre i 3 timer under omrøring og tilbakeløp til koking. Det filtreres varmt under kulltilsetning og filtratet fortynnes med aceton, hvorved den rå 2-(imidazol-4-yl)-l-hydroksy-etan-l,1-difosfonsyre utskilles. Denne omkrystalliseres fra vann, smeltepunkt 238-240° (spaltning).
Eksempel 2:
På tilsvarende måte som beskrevet i eksempel 1 oppnår man med utgangspunkt i l-metylimidazol-2-eddiksyrehydroklorid 2-(l-metylimidazol-2-yl)-l-hydroksyetan-l,1-difosfonsyremono-hydrat, smeltepunkt 261° (spaltning).
Utgangsmaterialet kan f.eks. fremstilles på følgende måte: 5,0 g (0,032 mol) l-metyl-2-cyanometyl-imidazolhydroklorid oppvarmes med 15 ml iseddik og 15 ml 36 <& hydrogenklorid 24 timer under tilbakeløp til koking. Deretter inndampes det under redusert trykk til tørrhet, resten opptas med 30 ml varm iseddik og frafiltreres fra uoppløst ammoniumklorid. Filtratet inndampes og blandes med aceton. Man oppnår 1-metyl-2-karboksymetyl-imidazolhydroklorid, smeltepunkt 163-164° .
Eksempel 3:
På tilsvarende måte som beskrevet i eksempel 1 oppnår man med utgangspunkt i 4(5)-metylimidazol-5(4)-eddiksyrehydroklorid 2 - [ 4(5)-metyl imidazol-5(4)-yl]-1-hydroksyetan-1,1-difos-fonsyre, smeltepunkt 217-218° (spaltning). Utgangsmaterialet, 4(5)-metylimidazol-5(4)-eddiksyrehydroklorid, kan fremstilles på tilsvarende måte som beskrevet i eksempel 2.
Eksempel 4:
14,8 g (0,051 mol) metandifosfonsyretetraetylester tilsettes dråpevis til en suspensjon av 2,4 g natriumhydrid i 35 ml absolutt tetrahydrofuran og omrøres ved romtemperatur inntil gassutviklingen opphører. Det tilsettes så porsjonsvis 7,6 g (0,0465 mol) l-metyl-2-klormetylimidazolhydroklorid. Reaksjonsblandingen oppvarmes under omrøring og tilbakeløp i 20 timer til koking. Deretter frafiltreres utfelt natrium-klorid og filtratet inndampes under redusert trykk. Man oppnår den rå 2-(l-metylimidazol-2-yl)etan-l,1-difosfonsyre-tetraetylesteren. 2,3 g (0,0065 mol) av den samme oppvarmes med 12 ml 36 % hydrogenklorid tinder tilbakeløp i 20 timer til koking. Etter inndampning og krystallisasjon av resten fra vandig metanol oppnår man 2-(l-metylimidazol-2-yl)etan-l,1-difosfonsyre, smeltepunkt 295° (spaltning).
Eksempel 5:
2,3 g (0,0062 mol) 2-(imidazol-2-yl)etan-l,1-difosfonsyre-tetraetylester oppløses i 20 ml metylenklorid, blandes med 4,8 ml trimetylbromsilan og får stå i 24 timer ved romtemperatur. Deretter inndampes det under redusert trykk og resten blandes med 10 ml metanol og 1 ml vann. Man oppnår 2-(imidazol-2-yl)etan-l,1-difosfonsyre, smeltepunkt 279-282°
(spaltning).
Utgangsmaterialet kan f.eks. fremstilles på følgende måte: 14,8 g (0,051 mol) metandifosfonsyretetraetylester tilsettes dråpevis til en suspensjon av 2,4 g natriumhydrid i 35 ml absolutt tetrahydrofuran og omrøres ved romtemperatur inntil avsluttet gassutvikling. Det innføres så porsjonsvis 11,3 g (0,0465 mol) l-benzyl-2-klormetylimidazolhydroklorid. Reaksjonsblandingen oppvarmes til koking under omrøring og tilbakeløp i 20 timer. Deretter frafiltreres det utfelte natriumkloridet og filtratet inndampes under redusert trykk. Man oppnår den råe 2-(l-benzylimidazol-2-yl)etan-l,1-difosfonsyretetraetylestern.
3,3 g (0,0072 mol) 2-(l-benzylimidazol-2-yl)etan-l,1-difosfonsyretetraetylester oppløses i 50 ml flytende ammoniakk og blandes gradvis under omrøring med 1,0 g natrium i små stykker, inntil den blå fargen av oppløsningen består over lengere tid. Deretter tilsettes porsjonsvis 2,35 g ammoniumklorid. Ammoniakken får fordampe, resten opptas med dietylester, filtreres og filtratet inndampes. Man oppnår på
denne måten 2-(imidazol-2-yl )etan-l,1-difosfonsyretetraetyl-ester som fargeløs olje.
Eksempel 6:
8,6 g (0,053 mol) imidazol-1-yleddiksyrehydroklorid oppvarmes med 7,1 ml 85 K> fosforsyre og 25 ml klorbenzen under omrøring og tilbakeløp til 100°. Deretter tilsettes det ved 100° dråpevis 13,9 ml fosfortriklorid, hvorved gassutvikling finner sted. Reaksjonsblandingen utskiller i løpet av 30 minutter en tykk masse. Det oppvarmes ytterligere 3 timer til 100° og den ovenstående klorbenzenen avdekanteres. Den tilbakeblivende seige massen oppvarmes med 40 ml 9-n saltsyre i 3 timer under omrøring og tilbakeløp til koking. Det filtreres varmt under kulltilsats og filtratet fortynnes med aceton, hvorved det utskilles rå 2-(imidazol-l-yl)-l-hydroksyetan-1,1-difosfonsyre, Denne omkrystalliseres fra vann, smeltepunkt 239° (spaltning).
Eksempel 7:
Analogt eksempel 5 oppnår man med utgangspunkt fra 2-(imidazol-l-yl)etan-l,1-difosfonsyretetraetylester ved behandling med trimetylbromsilan og opparbeidelse med vandig metanol 2-(imidazol-l-yl)etan-l,1-difosfonsyre, smeltepunkt 255" (spaltning).
Utgangsmaterialet kan fremstilles analogt eksempel 4 ved omsetning av p-toluensulfonsyre(imidazol-l-yl-metyl)ester med metandifosfonsyretetraetylester.
Eksempel 8:
3,4 g (0,0094 mol) 2-(l-benzylimidazol-2-yl)-l-hydroksy-l,1-etandifosfonsyre oppløses i 40 ml flytende ammoniakk og blandes gradvis under omrøring med 1,0 g natrium i små stykker inntil den blå fargen på oppløsnignen varer ved i lengere tid. Deretter tilsettes porsjonsvis 2,35 g ammoniumklorid. Ammoniakken får så fordampe, resten opptas med 20 ml varmt vann, filtres og filtratet blandes med 10 ml konsen-trert saltsyre. De utfelte krystallene filtreres og omkrystalliseres fra vandig metanol. Man oppnår på denne måten 2-(imidazol-2-yl)-l-hydroksyetandifosfonsyre, smeltepunkt 235° (spaltning).
Utgangsmaterialet kan f.eks. fremstilles på følgende måte: 19,7 g (0,1 mol) l-benzylimidazol-2-ylacetonitril oppvarmes med 13,4 ml 85 % fosforsyre og 50 ml klorbenzen under omrøring og tilbakeløp til 100°. Deretter tilsettes dråpevis 27 ml fosfortriklorid ved 100°, hvorved gassutvikling finner sted. Reaksjonsblandingen utskiller i løpet av 30 minutter en tykk masse. Det oppvarmes ytterligere 3 timer til 100° og den ovenstående klorbenzen avdekanteres. Den tilbakeblivende seige massen oppvarmes med 100 ml 9-n saltsyre i 3 timer under omrøring og tilbakeløp til koking. Det filtreres varmt under kulltilsats og filtratet avkjøles, hvorved l-amino-2-(1-benzylimidazo1-2-yl)-etan-l,1-difosfonsyre utskilles.
3,59 g (0,01 mol) l-amino-2-(l-benzylimidazol-2-yl)-etan-l,1-difosfonsyre oppløses i 20 ml l-n natronlut, blandes med 0,82 g natriumnitritt og avkjøles til 0° . Deretter tilsettes det langsomt, dråpevis under omrøring 18 ml 2-n saltsyre. Deretter omrører man ytterligere 1 time ved 0-10° og det utfelte produktet filtreres. Etter omkrystallisasjon fra vann oppnår man 2-(l-benzylimidazol-2-yl)-l-hydroksyetan-l,1-dif osf onsyre , smeltepunkt 171° (spaltning).
Eksempel 9:
På tilsvarende måte som beskrevet i eksemplene 1 til 8 kan man videre fremstille
2-[2-metylimidazol-4(5 )-yl]etan-l,1-difosfonsyre, smeltepunkt 261-262° (spaltning);
og
2-(2-metylimidazol-l-yl ) -1-hydroksyetan-1,1-difosfonsyre , smeltepunkt 245-246°,
og salter derav, f.eks. dinatriumsalter.
Claims (2)
1.
Analogifremgangsmåte for fremstilling av terapeutisk anvendbare heteroarylalkandifosfonsyrer med formelen
hvor Ri betyr en usubstituert eller med Ci-C4~alkyl substituert imidazolylrest og R2 betyr hydroksy eller hydrogen og deres salter,
karakterisert ved at man a) i en ved et substituerbart N-atom i resten R^ eventuelt
midlertidig beskyttet forbindelse med formelen
hvor Ri og R2 har de angitte betydningene, Xi betyr en funksjonelt omdannet og X2 en fri eller funksjonelt omdannet fosfonogruppe, overfører Xi og eventuelt X2 til den frie fosfonogruppen eller b) omsetter en på et substituerbart N-atom i resten Ri eventuelt midlertidig beskyttet forbindelse med formelen
hvor X3 betyr en karboksy—, karbamyl—, iminoeter—, imino-ester— eller cyanogruppe og Ri har den angitte betydningen, med fosforsyrling og fosfortriklorid, og
om ønsket overfører en oppnådd forbindelse til en annen forbindelse med formel I og/eller overfører en oppnådd fri forbindelse til et salt eller et oppnådd salt til den frie forbindelsen eller til et annet salt.
2.
Fremgangsmåte ifølge krav 1 for fremstilling av 2-(imidazol-l-yl )-l-hydroksy-etan-l,1-difosfonsyre eller et salt derav, karakterisert ved at tilsvarende, eventuelt substituerte utgangsmaterialer anvendes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH466686 | 1986-11-21 |
Publications (4)
Publication Number | Publication Date |
---|---|
NO874856D0 NO874856D0 (no) | 1987-11-20 |
NO874856L NO874856L (no) | 1988-05-24 |
NO173446B true NO173446B (no) | 1993-09-06 |
NO173446C NO173446C (no) | 1993-12-15 |
Family
ID=4280350
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO874856A NO173446C (no) | 1986-11-21 | 1987-11-20 | Analogifremgangsmaate til fremstilling av nye, terapeutisk aktive, substituerte alkandifosfonsyrer |
NO2001015C NO2001015I2 (no) | 1986-11-21 | 2001-09-04 | Zoledronsyre |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2001015C NO2001015I2 (no) | 1986-11-21 | 2001-09-04 | Zoledronsyre |
Country Status (27)
Country | Link |
---|---|
US (1) | US4939130A (no) |
EP (1) | EP0275821B1 (no) |
JP (1) | JP2744238B2 (no) |
KR (1) | KR960010752B1 (no) |
AT (1) | ATE72816T1 (no) |
AU (1) | AU607722B2 (no) |
CA (1) | CA1338937C (no) |
CY (1) | CY1827A (no) |
DD (1) | DD270533A5 (no) |
DE (2) | DE10199052I1 (no) |
DK (1) | DK174098B1 (no) |
ES (1) | ES2038692T4 (no) |
FI (1) | FI87570C (no) |
GR (1) | GR3003895T3 (no) |
HK (1) | HK114894A (no) |
HU (1) | HU199150B (no) |
IE (1) | IE59816B1 (no) |
IL (1) | IL84497A (no) |
LU (1) | LU90838I2 (no) |
MX (1) | MX9427A (no) |
NL (1) | NL300058I2 (no) |
NO (2) | NO173446C (no) |
NZ (1) | NZ222610A (no) |
PH (1) | PH24345A (no) |
PT (1) | PT86167B (no) |
SG (1) | SG92194G (no) |
ZA (1) | ZA878698B (no) |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3626058A1 (de) * | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3640938A1 (de) * | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
US5139786A (en) * | 1989-07-07 | 1992-08-18 | Ciba-Geigy Corporation | Topical formulations |
MX21452A (es) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
CA2107082A1 (en) * | 1991-04-27 | 1992-10-28 | Ichiro Mori | Triazole compounds |
US5391743A (en) * | 1992-05-29 | 1995-02-21 | Procter & Gamble Pharmaceuticals, Inc. | Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque |
AU666741B2 (en) * | 1992-05-29 | 1996-02-22 | Procter & Gamble Pharmaceuticals, Inc., The | Thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism |
US5753634A (en) * | 1992-05-29 | 1998-05-19 | The Procter & Gamble Company | Quaternary nitrogen containing phosphonate compounds, pharmaceutical compostions, and methods for treating abnormal calcium and phosphate metabolism |
DK0646119T3 (da) * | 1992-05-29 | 1998-12-14 | Procter & Gamble Pharma | Phosphonatforbindelser indeholdende kvaternært nitrogen til behandling af unormalt calcium- og phosphatstofskifte samt tan |
DE69329199D1 (de) * | 1992-05-29 | 2000-09-14 | Procter & Gamble Pharma | Schwefel-enthaltende phosphonat-verbindungen zur behandlung von abnormalem calzium- und phosphat- metabolismus |
US5763611A (en) * | 1992-05-29 | 1998-06-09 | The Procter & Gamble Company | Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
ES2133402T3 (es) * | 1992-06-30 | 1999-09-16 | Procter & Gamble Pharma | Composiciones, para el tratamiento de la artritis, que contienen fosfonatos y farmacos anti-inflamatorios no esteroideos. |
AU670337B2 (en) | 1992-11-30 | 1996-07-11 | Novartis Ag | Use of certain methanebisphosphonic acid derivatives in fracture healing |
GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
US5880111A (en) * | 1995-06-07 | 1999-03-09 | Farcasiu; Dan | Therapeutic derivations of diphosphonates |
IL115041A0 (en) * | 1995-08-23 | 1995-12-08 | Yissum Res Dev Co | Novel bisphosphonates process for their preparation and pharmaceutical compositions containing them |
DE69634487T2 (de) * | 1995-09-29 | 2006-01-05 | Novartis Ag | Verfahren zur behandlung navikularer krankheiten bei pferden |
DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
AU6452098A (en) * | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
DE19719680A1 (de) | 1997-05-09 | 1998-11-19 | Boehringer Mannheim Gmbh | Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz |
CA2343027A1 (en) * | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
EP0998932A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung |
EP0998933A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation |
US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
JP2003519154A (ja) * | 1999-12-22 | 2003-06-17 | メタバシス・セラピューティクス・インコーポレイテッド | 新規なビスアミダートホスホネートプロドラッグ |
US6562974B2 (en) | 2000-02-01 | 2003-05-13 | The Procter & Gamble Company | Process for making geminal bisphosphonates |
PE20011061A1 (es) | 2000-02-01 | 2001-11-20 | Procter & Gamble | Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato |
ATE304856T1 (de) * | 2000-06-20 | 2005-10-15 | Novartis Pharma Gmbh | Methode zur verabreichung von biphosphonaten |
RU2288722C2 (ru) | 2000-06-20 | 2006-12-10 | Новартис Аг | Способ введения бисфосфонатов |
US7563774B2 (en) * | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
SI1392313T1 (sl) | 2001-05-16 | 2007-08-31 | Novartis Ag | Kombinacija, ki vkljuäśuje n-5-4-(4-metil-piperazino-metil)-benzoilamido/-2-metilfenil-4-(3- piridil)-2pirimidin-amin in difosfonat |
PT1534265E (pt) * | 2002-07-30 | 2007-02-28 | Novartis Ag | Combinação de um inibidor da aromatase com um bisfosfonato |
EP1546110A4 (en) * | 2002-07-30 | 2008-03-26 | Univ Virginia | ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE |
JP2006500402A (ja) * | 2002-09-16 | 2006-01-05 | ノバルティス アクチエンゲゼルシャフト | 股関節骨折後における二次骨折の予防または低減化方法 |
PL212072B1 (pl) | 2002-12-20 | 2012-08-31 | Hoffmann La Roche | Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania |
EP1525207A2 (en) * | 2003-02-27 | 2005-04-27 | Teva Pharmaceutical Industries Limited | Process for purification of zoledronic acid |
EP1612212A1 (en) | 2003-07-03 | 2006-01-04 | Teva Pharmaceutical Industries Ltd | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
US20050049693A1 (en) * | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
US20050119230A1 (en) * | 2003-09-18 | 2005-06-02 | Alexandra Glausch | Pharmaceutical products comprising bisphosphonated |
MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
WO2005027921A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
US7638637B2 (en) * | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
EP2206717B1 (en) | 2003-12-23 | 2013-03-27 | Alchymars S.p.A. | A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof |
WO2005063717A1 (en) * | 2003-12-26 | 2005-07-14 | Natco Pharma Limited | An improved process for the preparation of zoledronic acid |
WO2006023515A2 (en) * | 2004-08-18 | 2006-03-02 | Metabasis Therapeutics, Inc. | Novel thiazole inhibitors of fructose 1,6-bisphosphatase |
WO2008128056A1 (en) * | 2004-10-08 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
EP1802641B8 (en) * | 2004-10-08 | 2012-03-07 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US7888527B2 (en) * | 2004-12-06 | 2011-02-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
KR20070092972A (ko) * | 2004-12-10 | 2007-09-14 | 테무릭크 가부시키가이샤 | 전이암 치료제 및 암 전이 억제제 |
AU2006214314B2 (en) | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
WO2006100687A1 (en) * | 2005-03-24 | 2006-09-28 | Dabur Pharma Ltd. | Disodium pamidronate aqueous formulation |
WO2006134603A1 (en) * | 2005-06-13 | 2006-12-21 | Jubilant Organosys Limited | Process for producing bisphosphonic acids and forms thereof |
AR054673A1 (es) * | 2005-07-28 | 2007-07-11 | Gador Sa | Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende |
KR20080042131A (ko) * | 2005-09-12 | 2008-05-14 | 닥터 레디스 레보러터리즈 리미티드 | 졸레드론산의 결정성 삼수화물 |
EP1986623A2 (en) * | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
EP1987013A1 (en) * | 2006-02-09 | 2008-11-05 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
EP2001486A4 (en) * | 2006-03-17 | 2010-12-29 | Univ Illinois | BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS |
WO2007125521A2 (en) * | 2006-05-02 | 2007-11-08 | Ranbaxy Laboratories Limited | Polymorphic form of zoledronic acid and processes for their preparation |
AU2007323557A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
AU2007323540A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
AU2007323618A1 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
US20100144679A1 (en) * | 2007-03-21 | 2010-06-10 | Duke University | Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture |
US20090082312A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched zoledronic acid |
ITPA20070034A1 (it) * | 2007-10-30 | 2009-04-30 | Tetrapharm S R L | Bifosfonati geminali, loro preparazione e loro impiego in campo oncologico. |
EP2225252B1 (en) | 2007-11-30 | 2012-06-27 | Novartis AG | C2-c5-alkyl-imidazole-bisphosphonates |
EP2234608A2 (en) | 2007-12-11 | 2010-10-06 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
CA2720418A1 (en) * | 2008-04-04 | 2009-10-08 | Novartis Ag | Pharmaceutical composition with bisphosphonate |
PL213599B1 (pl) | 2008-10-31 | 2013-03-29 | Politechnika Gdanska | Sposób otrzymywania kwasu [1-hydroksy-2-(1H-imidazol-1-ilo)-etylideno] bisfosfonowego |
US20100130746A1 (en) * | 2008-11-26 | 2010-05-27 | Martin Kas | Process for Making Zoledronic Acid |
EP2192126B1 (en) | 2008-11-26 | 2013-03-27 | Synthon B.V. | Process for making zoledronic acid |
CA2746612A1 (en) * | 2008-12-23 | 2010-07-08 | Novartis Ag | Phenylalkyl-imidazole-bisphosphonate compounds |
EP2458996B1 (en) * | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
DK2459176T3 (en) | 2009-07-31 | 2017-12-04 | Gruenenthal Gmbh | Crystallization process and bioavailability |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
WO2011028737A2 (en) | 2009-09-01 | 2011-03-10 | Duke University | Bisphosphonate compositions and methods for treating heart failure |
US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
JP2013525294A (ja) | 2010-04-16 | 2013-06-20 | ノバルティス アーゲー | インプラント骨結合を改善するための方法および組成物 |
WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
HU230718B1 (hu) | 2011-02-08 | 2017-11-28 | Richter Gedeon Nyrt. | Új eljárás dronsavak gyógyszeripari előállítására |
CN102276650A (zh) * | 2011-06-22 | 2011-12-14 | 苏州莱克施德药业有限公司 | 一种唑来膦酸的制备方法 |
EP2780021A4 (en) | 2011-11-16 | 2015-08-05 | Univ Duke | BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND / OR REDUCING HEART FAILURE |
CN102617642B (zh) * | 2012-02-24 | 2015-11-18 | 江苏省原子医学研究所 | 一种含2-乙基咪唑的双膦酸化合物及其制备方法和应用 |
CN102659840B (zh) * | 2012-05-10 | 2013-08-14 | 苏州普瑞诺药物技术有限公司 | 咪唑双膦酸类化合物及其可药用盐及药物用途 |
US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
US8865757B1 (en) | 2014-05-28 | 2014-10-21 | Antecip Bioventures Ii Llp | Therapeutic compositions comprising imidazole and imidazolium compounds |
US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
US9669040B2 (en) | 2012-05-14 | 2017-06-06 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9427403B2 (en) | 2012-05-14 | 2016-08-30 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9895383B2 (en) | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9675626B2 (en) | 2012-05-14 | 2017-06-13 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
US9655908B2 (en) | 2012-05-14 | 2017-05-23 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US8802658B2 (en) | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
US9662343B2 (en) | 2012-05-14 | 2017-05-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US9289441B2 (en) | 2014-08-08 | 2016-03-22 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US9616078B2 (en) | 2012-05-14 | 2017-04-11 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
US9012432B2 (en) | 2013-03-08 | 2015-04-21 | Levolta Pharmaceuticals, Inc. | Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis |
CN114404427A (zh) | 2014-02-13 | 2022-04-29 | 配体药物公司 | 前药化合物及其用途 |
US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
EP3737676B1 (en) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
RU2725962C2 (ru) * | 2020-02-12 | 2020-07-07 | Акционерное Общество "Фарм-Синтез" | Способ приготовления фармацевтической композиции на основе золедроновой кислоты в виде раствора для инфузий для лечения онкологических заболеваний и способ получения фармацевтической композиции на основе золедроновой кислоты в виде концентрата для приготовления раствора для инфузий для лечения онкологических заболеваний |
CN114057648B (zh) * | 2020-07-30 | 2024-02-20 | 常州方圆制药有限公司 | 一种唑来膦酸中间体杂质的制备方法 |
KR20220115062A (ko) | 2021-02-09 | 2022-08-17 | (주)오스티오뉴로젠 | 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0084822B1 (de) * | 1982-01-27 | 1986-01-08 | Schering Aktiengesellschaft | Diphosphonsäure-Derivate und diese enthaltende pharmazeutische Präparate |
DE3203307A1 (de) * | 1982-01-27 | 1983-07-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Phosphonate, und diese enthaltende pharmazeutische verbindungen |
DE3203308A1 (de) * | 1982-01-27 | 1983-07-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Diphosphonsaeure-derivate und diese enthaltende pharmazeutische praeparate |
DE3428524A1 (de) * | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
IL77243A (en) * | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
DE3626058A1 (de) * | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
-
1987
- 1987-11-16 IL IL8449787A patent/IL84497A/en not_active IP Right Cessation
- 1987-11-16 DE DE2001199052 patent/DE10199052I1/de active Pending
- 1987-11-16 EP EP87810664A patent/EP0275821B1/de not_active Expired - Lifetime
- 1987-11-16 DE DE8787810664T patent/DE3776880D1/de not_active Expired - Lifetime
- 1987-11-16 ES ES87810664T patent/ES2038692T4/es not_active Expired - Lifetime
- 1987-11-16 AT AT87810664T patent/ATE72816T1/de active
- 1987-11-18 FI FI875096A patent/FI87570C/fi active Protection Beyond IP Right Term
- 1987-11-19 NZ NZ222610A patent/NZ222610A/xx unknown
- 1987-11-19 PT PT86167A patent/PT86167B/pt unknown
- 1987-11-19 MX MX942787A patent/MX9427A/es unknown
- 1987-11-19 CA CA000552209A patent/CA1338937C/en not_active Expired - Lifetime
- 1987-11-20 DD DD87309267A patent/DD270533A5/de not_active IP Right Cessation
- 1987-11-20 NO NO874856A patent/NO173446C/no not_active IP Right Cessation
- 1987-11-20 IE IE314887A patent/IE59816B1/en active Protection Beyond IP Right Term
- 1987-11-20 PH PH36100A patent/PH24345A/en unknown
- 1987-11-20 AU AU81453/87A patent/AU607722B2/en not_active Expired
- 1987-11-20 DK DK198706095A patent/DK174098B1/da not_active IP Right Cessation
- 1987-11-20 HU HU875160A patent/HU199150B/hu unknown
- 1987-11-20 JP JP62292198A patent/JP2744238B2/ja not_active Expired - Lifetime
- 1987-11-20 ZA ZA878698A patent/ZA878698B/xx unknown
- 1987-11-20 KR KR1019870013063A patent/KR960010752B1/ko not_active IP Right Cessation
-
1989
- 1989-02-27 US US07/315,962 patent/US4939130A/en not_active Expired - Lifetime
-
1992
- 1992-02-27 GR GR910402106T patent/GR3003895T3/el unknown
-
1994
- 1994-07-11 SG SG92194A patent/SG92194G/en unknown
- 1994-10-20 HK HK114894A patent/HK114894A/xx not_active IP Right Cessation
-
1995
- 1995-12-01 CY CY182795A patent/CY1827A/xx unknown
-
2001
- 2001-09-04 NO NO2001015C patent/NO2001015I2/no unknown
- 2001-09-14 NL NL300058C patent/NL300058I2/nl unknown
- 2001-09-19 LU LU90838C patent/LU90838I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO173446B (no) | Analogifremgangsmaate til fremstilling av nye, terapeutiskaktive, substituerte alkandifosfonsyrer | |
KR900004043B1 (ko) | 디포스폰산유도체, 이들의 제조방법 및 이들을 함유하는 제약조성물 | |
FI89366B (fi) | Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat | |
DK168630B1 (da) | Aromatiske substituerede azacycloalkyl-1-hydroxy-alkan-1,1-diphosphonsyrer og deres salte, fremgangsmåde til fremstilling deraf samt farmaceutisk præparat med indhold deraf | |
NO176569B (no) | Analogifremgangsmåte for fremstilling av nye, terapeutisk aktive, aromatisk substituerte alkylaminoalkandifosfonsyrer | |
FI92704C (fi) | Menetelmä terapeuttisesti käyttökelpoisten aromaattisesti substituoitujen alkyyliaminoalkaanidifosfonihappojen valmistamiseksi | |
NO174152B (no) | Analogifremgangsm}te for fremstilling av N-substituerte aminoalkandifosfonsyrer | |
AU605203B2 (en) | Novel substituted aminomethanediphosphonic acids | |
US5057505A (en) | Substituted aminomethanediphosphonic acids and use in medicaments | |
US5110807A (en) | Araliphatylaminoalkanediphosphonic acids | |
US5190930A (en) | Araliphatylaminoalkanediphosphonic acids | |
NZ240254A (en) | Benzoheterocyclylalkylaminoalkanediphosphonic acid derivatives and | |
SI8810711A (sl) | Postopek za pripravo novih substituiranih alkandifosfonskih kislin | |
HRP940453A2 (en) | Novel substituted alkanediphosphonic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: ZOLEDRONSYRE OG SALTER DERAV; NAT. REG. NO/DATE: NO , 00/393 20010607; FIRST REG. NO/DATE: CH , 55463 20001128 Spc suppl protection certif: 2001015 Filing date: 20010904 Extension date: 20121120 |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Free format text: PRODUCT NAME: ZOLEDRONSYRE OG SALTER DERAV; NAT. REG. NO/DATE: NO , 00/393 20010607; FIRST REG. NO/DATE: CH , 55463 20001128 Spc suppl protection certif: 2001015 |